Authors: Anthony Matthews, Anthony Matthews, Ian J Douglas, Krishnan Bhaskaran, Liam Smeeth, Sinéad M Langan
Published: June 1, 2016
A matched cohort study of 145,104 PDE5 inhibitor users and 560,933 controls across 3.44 million person-years of follow-up identified 1,315 incident melanoma cases. The apparent association between PDE5 inhibitor use and melanoma (HR = 1.14, 95% CI 1.01-1.29, p = 0.04) was explained by confounding from sun exposure. Negative control outcomes related to sun exposure showed similar risk increases: basal cell carcinoma (HR = 1.15, 95% CI 1.11-1.19, p < 0.001) and solar keratosis (HR = 1.21, 95% CI 1.17-1.25, p < 0.001). Post hoc analysis confirmed solar keratosis was strongly associated with future PDE5 inhibitor use (OR = 1.28, 95% CI 1.23-1.34, p < 0.001), indicating greater sun exposure among these men. No dose-response relationship was found (p-trend = 0.83).
